Read More Pharma Industry News Daiichi Sankyo launches development of oral triple combination tablets for LDL cholesterol management in Europe Daiichi Sankyo (TYO: 4568) begins developing oral triple therapy with bempedoic acid, ezetimibe, and statins to transform LDL cholesterol management in Europe. bySoujanya RaviAugust 30, 2025